Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Identification of direct transcriptional targets of NFATC2 that promote β cell proliferation
Shane P. Simonett, … , Mark P. Keller, Alan D. Attie
Shane P. Simonett, … , Mark P. Keller, Alan D. Attie
Published September 7, 2021
Citation Information: J Clin Invest. 2021;131(21):e144833. https://doi.org/10.1172/JCI144833.
View: Text | PDF
Research Article Cell biology Endocrinology

Identification of direct transcriptional targets of NFATC2 that promote β cell proliferation

  • Text
  • PDF
Abstract

The transcription factor NFATC2 induces β cell proliferation in mouse and human islets. However, the genomic targets that mediate these effects have not been identified. We expressed active forms of Nfatc2 and Nfatc1 in human islets. By integrating changes in gene expression with genomic binding sites for NFATC2, we identified approximately 2200 transcriptional targets of NFATC2. Genes induced by NFATC2 were enriched for transcripts that regulate the cell cycle and for DNA motifs associated with the transcription factor FOXP. Islets from an endocrine-specific Foxp1, Foxp2, and Foxp4 triple-knockout mouse were less responsive to NFATC2-induced β cell proliferation, suggesting the FOXP family works to regulate β cell proliferation in concert with NFATC2. NFATC2 induced β cell proliferation in both mouse and human islets, whereas NFATC1 did so only in human islets. Exploiting this species difference, we identified approximately 250 direct transcriptional targets of NFAT in human islets. This gene set enriches for cell cycle–associated transcripts and includes Nr4a1. Deletion of Nr4a1 reduced the capacity of NFATC2 to induce β cell proliferation, suggesting that much of the effect of NFATC2 occurs through its induction of Nr4a1. Integration of noncoding RNA expression, chromatin accessibility, and NFATC2 binding sites enabled us to identify NFATC2-dependent enhancer loci that mediate β cell proliferation.

Authors

Shane P. Simonett, Sunyoung Shin, Jacob A. Herring, Rhonda Bacher, Linsin A. Smith, Chenyang Dong, Mary E. Rabaglia, Donnie S. Stapleton, Kathryn L. Schueler, Jeea Choi, Matthew N. Bernstein, Daniel R. Turkewitz, Carlos Perez-Cervantes, Jason Spaeth, Roland Stein, Jeffery S. Tessem, Christina Kendziorski, Sündüz Keleş, Ivan P. Moskowitz, Mark P. Keller, Alan D. Attie

×

Figure 5

Identification of NFATC2-dependent enhancer loci in human islets.

Options: View larger image (or click on image) Download as PowerPoint
Identification of NFATC2-dependent enhancer loci in human islets.
ncRNA ...
ncRNA expression was measured in 5 separate human islet samples. (A) Volcano plots (–log10 P value versus log2 fold-change) for expression of 91,712 ncRNAs (left panel) and 231,232 ATAC peaks (right panel) in human islets in response to Ad-ca-Nfatc2 versus Ad-GFP. DE ncRNAs or DA ATAC peaks (P < 0.05, DESeq2) that contain an NFATC2 binding peak within 1 Kbp are shown as colored circles. Blue, suppressed; red, increased. Numbers are shown for each. Chromatin accessibility was measured in 3 separate human islet samples. (B) The log2 fold change in the ATAC peak amplitude versus ncRNA expression for 1105 combined loci containing an NFATC2 binding peak within 1 Kbp. Colored circles designate loci where both ATAC peak and ncRNA expression were significantly different in response to ca-Nfatc2 (P < 0.05, DESeq2). Black dots indicate loci where ATAC peak did not change but yielded a DE ncRNA. Numbers are shown for each. Distribution of NFATC2-dependent ncRNAs and ATAC peaks (C) and colocalized ncRNA-ATAC peaks (D) among annotated genomic compartments. (E) Browser views of NFATC2-dependent enhancer loci proximal to NR4A1, ALDH18A1, STIL, and BIRC5 genes. NFATC2 ChIP-Seq in 8 separate human islet donors. ATAC-Seq in 3 separate human islet donors in response to Ad-GFP or Ad-ca-Nfatc2. Aggregate ncRNA-Seq in 5 separate human islet donors for transcripts identified on forward (+) or reverse (–) strands (see Methods) in response to Ad-GFP or Ad-ca-Nfatc2 treatments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts